Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

Abstract Background Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadvantages such as adverse events, practical burden fo...

Full description

Bibliographic Details
Main Authors: Celia A. J. Michielsens, Nadine Boers, Nathan den Broeder, Mark H. Wenink, Aatke van der Maas, Elien A. M. Mahler, Michelle L. M. Mulder, Désirée van der Heijde, Frank H. J. van den Hoogen, Lise M. Verhoef, Alfons A. den Broeder
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Trials
Subjects:
Spondyloarthritis
Psoriatic arthritis
Dose reduction
Tapering
Randomised controlled trial
TNF inhibitors
Online Access:https://doi.org/10.1186/s13063-019-4000-5

Internet

https://doi.org/10.1186/s13063-019-4000-5

Similar Items